FRI0605 EFFECTIVENESS AND SAFETY OF OFF-LABEL USE OF TOCILIZUMAB IN AUTOIMMUNE DISEASES : A MULTICENTER STUDY IN INTERNAL MEDICINE DEPARTMENTS
Martin Michaud(Centre Hospitalier Universitaire de Toulouse), F. Gaches, F. Rétornaz(Hôpital Européen), G. Urbanski(Centre Hospitalier Universitaire d'Angers), Thomas Sené(Groupe Hospitalier Diaconesses Croix Saint-Simon), Olivier Lidove(Groupe Hospitalier Diaconesses Croix Saint-Simon), Laurent Alric, L. Sailler(Université Fédérale de Toulouse Midi-Pyrénées), Boris Bienvenu(Hôpital Saint Joseph), F. Catros(Hôpital Joseph-Ducuing), Sophie Ancellin(Hôpital Joseph-Ducuing), S Lassoued(Groupe Cahors (France)), Pascal Chazerain(Groupe Hospitalier Diaconesses Croix Saint-Simon), Jean Thomas Giraud(Centre Hospitalier de Bigorre), Laurent Chiche(Hôpital Européen), L. Caudrelier(Groupe Cahors (France))
Cited by 1
Related Papers
Proinflammatory Cytokines, Aging, and Age-Related Diseases
|Journal of the American Medical Directors Association|2013|1.1k
Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients*
|British Journal of Dermatology|2021|414
Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies
|Journal of Allergy and Clinical Immunology|2017|316
COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study
|The Lancet Rheumatology|2021|292